This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies and provide an updated account of the status of bromelain and N-acetylcysteine in cancer therapy. The volume will develop the idea of using these two drugs as a combination formulation for mucin-depleting effects.

This thesis focuses on the development of gold- and non-classical platinum-based anti-cancer agents that display distinctively different anti-cancer mechanisms compared to the commonly used cisplatin. These metal complexes contain N-heterocyclic carbene (NHC) ligands which are able to form strong M-C(NHC) bonds, conferring high stability and favorable lipophilicity, reactivity and binding specificity of metal complexes on biomolecules. The author demonstrates significant advances made in anti-cancer gold(III), gold(I) and platinum(II) complexes. Detailed chemical synthesis, in vitro and/or in vivo anti-cancer activities are clearly presented including: (i) a class of Au(III) complexes containing a highly fluorescent N^N^N ligand and NHC ligand that simultaneously act as fluorescent thiol "switch-on" probes and anti-cancer agents; (ii) a dinuclear gold(I) complex with a mixed diphosphine and bis(NHC) ligand displaying favorable stability and showing significant inhibition of tumor growth in two independent mice models with no observable side effects; and (iii) a panel of stable luminescent cyclometalated platinum(II) complexes exhibiting high specificity to localize to the endoplasmic reticulum (ER) domain, inducing ER stress and cell apoptosis. These works highlight the clinical potential that gold and platinum complexes offer for cancer treatment.

This book is about "Angiogenesis". A process in which new vasculature is formed from pre-existing capillaries. Angiogenesis process is associated with the proliferation and growth of both physiologically normal and neoplastic tissues, through the formation of vascular supply, essential for delivering growth requirements such as oxygen and nutrients. The book describes more than 100 genes and their key regulatory functions in the context of normal healthy condition, disease and malignancy, cancer proliferation and progression. New insights into the role of angiogenesis and the therapeutic inhibition of its regulators are investigated, due to the great potential for exploitation in the development of a novel treatment for cancer. New scientists, junior researchers and biomedical science students will find this book an invaluable introductory reference to their insight about angiogenesis and angiogenic role of more than 100 angiogenes and their role in healthy, disease and malignant conditions.

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

This volume focuses on the roles of long non-coding RNAs (lncRNAs) in contexts ranging from human cancers to cardiovascular disease and ageing. The role of lncRNAs in X-inactivation and those lncRNAs derived from pseudogenes, past retroelements integrated within the human genome, as well as the role these pseudogene-derived lncRNAs play in cancer development are discussed in detail. Further, the book examines the function of lncRNAs in diseases such as diabetes, in smooth muscle formation, and in the modulation of nuclear receptors, as well as in connection with perspectives on the development of personalized therapeutics. It offers an appealing and insightful resource for scientists and clinicians alike.

This is the first book to provide a broad framework for obtaining an in depth understanding of the state-of-the-art knowledge on abnormalities of non-coding RNAs found to be associated with colorectal cancer pathogenesis. Readers will discover possible mechanisms underlying the substantial roles played by non-coding RNAs in molecular hallmarks of colorectal cancer. This work further provides the comprehensive overview and novel insights into using of non-coding RNAs as colorectal cancer biomarkers enabling early detection of the disease, prognostic stratification of the patients and prediction of therapeutic response. The reader is introduced to the overview of modern non-coding RNAs-based therapeutic strategies, and summary of their preclinical testing performed in colorectal cancer. The work is written for researchers who want to explore current state of the knowledge in this interesting field of molecular oncology.

This book discusses properties of apoptosis and other cell death modalities in cancer pathogenesis and treatment. Its nine chapters discuss modulation of anti-tumor inflammatory and immune responses, effects on the tumor microenvironment, to strategies for improving pro-apoptotic therapies, mechanisms and implications for disease pathogenesis, axl and mer receptor tyrosine kinases, immunogenic apoptotic cell death and anti-cancer immunity and cancer cell death-inducing radiotherapy. This book places the onco-biology of apoptosis in clear and objective perspective through an expertly synthesized series of reviews. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy is a deft and thorough exploration of cutting-edge research in apoptosis and anti-cancer mechanisms from basic biology to oncology. It highlights a rapidly growing field within cancer research and is essential reading for oncologists, biochemists and advanced graduate students alike.

This book aims to bridge the gap in understanding how protein-tyrosine phosphatases (PTPs), which carry out the reverse reaction of tyrosine phosphorylation, feature in cancer cell biology. The expertly authored chapters will first review the general features of the PTP superfamily, including their overall structure and enzymological properties; use selected examples of individual PTP superfamily members, to illustrate emerging data on the role of PTPs in cancer; and will review the current status of PTP-based drug development efforts. Protein Tyrosine Phosphatases in Cancer,from renowned researchers Benjamin Neel and Nicholas Tonks, is invaluable reading for researchers in oncology, stem cell signaling,and biochemistry.

Leading researchers are specially invited to provide a complete understanding of a key topic within the multidisciplinary fields of physiology, biochemistry and pharmacology. In a form immediately useful to scientists, this periodical aims to filter, highlight and review the latest developments in these rapidly advancing fields.

This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.

Experts from around the world review the current field of the immunobiology of heat shock proteins, and provide a comprehensive account of how these molecules are spearheading efforts in the understanding of various pathways of the immune system. This one-stop resource contains numerous images to both help illustrate the research on heat shock proteins, and better clarify the field for the non-expert. Heat shock proteins (HSPs) were discovered in 1962 and were quickly recognized for their role in protecting cells from stress. Twenty years later, the immunogenicity of a select few HSPs was described, and for the past 30 years, these findings have been applied to numerous branches of immunology, including tumor immunology and immunosurveillance, immunotherapy, etiology of autoimmunity, immunotherapy of infectious diseases, and expression of innate receptors. While HSPs can be used to manipulate immune responses by exogenous administration, they appear to be involved in initiation of de novo immune responses to cancer and likely in the maintenance of immune homeostasis.

2009 Choice Outstanding Academic Title 2009 Association of American University Presses Award for Jacket Design The stories of 70 women living in the aftermath of breast cancer Chemo brain. Fatigue. Chronic pain. Insomnia. Depression. These are just a few of the ongoing, debilitating symptoms that plague some breast-cancer survivors long after their treatments have officially ended. While there are hundreds of books about breast cancer, ranging from practical medical advice to inspirational stories of survivors, what has been missing until now is testimony from the thousands of women who continue to struggle with persistent health problems. After the Cure is a compelling read filled with fascinating portraits of more than seventy women who are living with the aftermath of breast cancer. Emily K. Abel is one of these women. She and her colleague, Saskia K. Subramanian, whose mother died of cancer, interviewed more than seventy breast cancer survivors who have suffered from post-treatment symptoms. Having heard repeatedly that "the problems are all in your head," many don't know where to turn for help. The doctors who now refuse to validate their symptoms are often the very ones they depended on to provide life-saving treatments. Sometimes family members who provided essential support through months of chemotherapy and radiation don't believe them. Their work lives, already disrupted by both cancer and its treatment, are further undermined by the lingering symptoms. And every symptom serves as a constant reminder of the trauma of diagnosis, the ordeal of treatment, and the specter of recurrence. Most narratives about surviving breast cancer end with the conclusion of chemotherapy and radiation, painting stereotypical portraits of triumphantly healthy survivors, women who not only survive but emerge better and stronger than before. Here, at last, survivors step out of the shadows and speak compellingly about their "real" stories, giving voice to the complicated, often painful realities of life after the cure. This book received funding from the Susan G. Komen Foundation.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

This volume will introduce new terminology to the field of oncology, subdividing it into oncokinetics-the mechanics of the tumor cells as they arise and spread throughout the body-and oncodynamics-the impact of abnormal cues generated by tumors on the physiological functioning of the body. The volume will outline the importance of oncodynamics from both a cancer patient's and a caregiver's perspectives, stressing its significant impact on cancer patient functionality and the opportunity that cancer researchers will have to develop cross-disciplinary interactions and predict potential consequences of tumors and/or treatment.

This book surveys recent advances in theranostics based on magnetic nanoparticles, ultrasound contrast agents, silica nanoparticles and polymeric micelles. It presents magnetic nanoparticles, which offer a robust tool for contrast enhanced MRI imaging, magnetic targeting, controlled drug delivery, molecular imaging guided gene therapy, magnetic hyperthermia, and controlling cell fate. Multifunctional ultrasound contrast agents have great potential in ultrasound molecular imaging, multimodal imaging, drug/gene delivery, and integrated diagnostics and therapeutics. Due to their diversity and multifunctionality, polymeric micelles and silica-based nanocomposites are highly capable of enhancing the efficacy of multimodal imaging and synergistic cancer therapy. This comprehensive book summarizes the main advances in multifunctional nanoprobes for targeted imaging and therapy of gastric cancer, and explores the clinical translational prospects and challenges. Although more research is needed to overcome the substantial obstacles that impede the development and availability of nanotheranostic products, such nontrivial nanoagents are expected to revolutionize medical treatments and help to realize the potential of personalized medicine to diagnose, treat, and follow-up patients with cancer. Zhifei Dai is a Professor at the Department of Biomedical Engineering, College of Engineering, Peking University, China.

This volume explores the latest developments in the study of the mechanisms, diagnostics, screening methods, and therapeutics of colorectal cancer. The book's chapters are divided into three parts: the chapters in Part One examine techniques used to study the molecular mechanisms in colorectal cancer development and progression. Part Two focuses on the innovative tools used to diagnose and detect cancer lesions in the early stages of cancer. Finally, Part Three discusses recent advancements in treating colorectal tumors and identifying new therapeutic molecules for treatment. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Colorectal Cancer: Methods and Protocols is a valuable resource for any scientist and researcher interested in this field of study.

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

This volume details our current understanding of the architecture and signaling capabilities of the B cell antigen receptor (BCR) in health and disease. The first chapters review new insights into the assembly of BCR components and their organization on the cell surface. Subsequent contributions focus on the molecular interactions that connect the BCR with major intracellular signaling pathways such as Ca2+ mobilization, membrane phospholipid metabolism, nuclear translocation of NF-kB or the activation of Bruton's Tyrosine Kinase and MAP kinases. These elements orchestrate cytoplasmic and nuclear responses as well as cytoskeleton dynamics for antigen internalization. Furthermore, a key mechanism of how B cells remember their cognate antigen is discussed in detail. Altogether, the discoveries presented provide a better understanding of B cell biology and help to explain some B cell-mediated pathogenicities, like autoimmune phenomena or the formation of B cell tumors, while also paving the way for eventually combating these diseases.

This vital collection provides a unique set of techniques to explore the clinical, pathological, and research aspects of the management of patients with esophageal adenocarcinoma. Beginning with an introduction to the basic features of esophageal adenocarcinoma, the book continues with clinical protocols for the management of the cancer, pathological methods for management of the patients and research, as well as protocols for molecular research, which could aid researchers in furthering our understanding of pathogenesis as well as in identifying new targets for the treatment and prevention of adenocarcinoma. Written for the highly successful Methods in Molecular Biology series, chapters include introductions on their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Esophageal Adenocarcinoma: Methods and Protocols is a valuable guide to stimulate specialists from various disciplines in their continuing research into esophageal adenocarcinoma and translating that research into improving the management of this cancer of rising importance.

This work describes the importance of tumor microenvironment in favouring tumor progression and angiogenesis. Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment and requires the functional activities of a number of molecules, including angiogenic factors, extracellular matrix proteins, adhesion molecules and proteolytic enzymes. In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors for endothelial cells, that stimulate the growth of the blood vessels of the host or the down-regulation of natural angiogenesis inhibitors. In particular, the inflammatory infiltrate may contribute to tumor angiogenesis, and there are many reports of associations between tumor inflammatory infiltrate, vascularity and prognosis. New therapeutic approaches have been developed with the aim to control tumor angiogenesis through targeting of different components of tumor microenvironment.

This volume explores the evolution of bacterial cancer therapy and describes the modern techniques used in therapy today. The chapters in this book cover a broad range of topics such as the development of tumor-targeting Salmonella typhimurium A1-R, a microfluidic device for precise quantification of the interactions between tumor-targeting bacteria and tumor tissue, non-invasive in vivo imaging of bacteria-mediated cancer therapy using bio-luminescent bacteria, methods to achieve remote-control of therapeutic gene expression in tumor-targeting bacteria, and cell-cycle decoy of cancer cells resistant to cytotoxic drugs to drug sensitivity by S. typhimurium A1-R. This book concludes with a chapter on the future potential of bacterial therapy of cancer. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Thorough and informative, Bacterial Therapy of Cancer: Methods and Protocols is a valuable resource for anyone who is interested in cancer and bacterial therapy.

This thesis presents the development of theranostic gold nanostars (GNS) for multimodality cancer imaging and therapy. Furthermore, it demonstrates that a novel two-pronged treatment, combining immune-checkpoint inhibition and GNS-mediated photothermal nanotherapy, can not only eradicate primary treated tumors but also trigger immune responses to treat distant untreated tumors in a mouse animal model. Cancer has become a significant threat to human health with more than eight million deaths each year, and novel methods for cancer management to improve patients' overall survival are urgently needed. The developed multifunctional GNS nanoprobe with tip-enhanced plasmonics in the near-infrared region can be combined with (1) surface-enhanced Raman spectroscopy (SERS), (2) two-photon photoluminescence (TPL), (3) X-ray computed tomography (CT), (4) magnetic resonance imaging (MRI), (5) positron emission tomography (PET), and (6) photothermal therapy (PTT) for cancer imaging and treatment. The ability of the GNS nanoprobe to detect submillimeter intracranial brain tumors was demonstrated using PET scan - a superior non-invasive imaging modality - in a mouse animal model. In addition, delayed rechallenge with repeated cancer cell injection in cured mice did not lead to new tumor formation, indicating generation of a memorized immune response to cancer. The biocompatible gold nanostars with superior capabilities for cancer imaging and treatment have great potential for translational medicine applications.

Cancer is a multifaceted disease and overwhelmingly increasing experimental evidence has helped us to develop a deeper understanding of the role of signal transduction cascades in cancer development and progression. Tissue microarrays and next generation sequencing technologies have assisted us to gather missing pieces of jigsaw puzzle and we now know that deregulation of spatio-temporally controlled signaling cascades play fundamental role in metastasis and resistance against wide ranging therapeutics. This book offers a balanced overview of the rapidly emerging cutting edge research in molecular oncology and good source of knowledge for established oncologists, basic and medical students and pharmaceutical industry associated R&D departments.